Printer Friendly Version 

Investor Relations Home

Webcast ImageWebcast
2014 Deutsche Bank BioFEST (Live)
12/01/14 at 12:00 p.m. ET
2014 Deutsche Bank BioFEST
Monday, December 1, 2014  through Tuesday, December 2, 2014 
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
26th Annual Piper Jaffray Healthcare Conference (Live)
12/02/14 at 12:00 p.m. ET
26th Annual Piper Jaffray Healthcare Conference
Tuesday, December 2, 2014  through Wednesday, December 3, 2014 
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Isis Pharmaceuticals’ Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting (Live)
12/08/14 at 9:00 a.m. ET
Isis Pharmaceuticals’ Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting
Monday, December 8, 2014 9:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
ISIS (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$51.79
Change (%) Stock is Down 0.96 (1.82%)
Volume813,490
Data as of 11/28/14 1:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
2013 Interactive Annual Report

Recent Press ReleasesMore >>
DateTitle 
11/25/14Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Children With Spinal Muscular Atrophy
-- Isis Earns $27 Million Milestone Payment -- CHERISH Trial to Enroll 120 Children With SMA at Clinical Centers Globally CARLSBAD, Calif., Nov. 25, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in approximately 120 non-ambulatory children with spinal muscular atrophy (SMA).  SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness.  The Phase 3 study,... 
Printer Friendly Version
11/20/14ISIS-STAT3 Rx and ISIS-AR Rx Data Presented by AstraZeneca at European Cancer Symposium
CARLSBAD, Calif., Nov. 20, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from two drugs in its anti-cancer franchise will be presented by researchers at AstraZeneca in three presentations at the 26th European Organization for Research and Treatment of Cancer (EORTC) – the National Cancer Institute (NCI) – and the American Association for Cancer Research (AACR) symposium.  Results from a Phase 1/2 clinical study presented today provided preliminary evide... 
Printer Friendly Version
11/18/14Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Nov. 18, 2014-- Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that new two-year data from a phase 3 long-term extension study of KYNAMRO® (mipomersen sodium) injection was presented at a scientific session at the annual American Heart Association meeting in Chicago, IL. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a sign... 
Printer Friendly Version
11/18/14Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting
- Webcast scheduled on Monday, December 8 at 9:00 a.m. Eastern Time CARLSBAD, Calif., Nov. 18, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Monday, December 8, 2014 at 9:00 a.m. Eastern Time to discuss the ISIS-FXIRx data presented at the 56th American Society of Hematology Annual Meeting and Exposition.  Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.isispharm.com.  A w... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
12/01/14
through
12/02/14
2014 Deutsche Bank BioFEST
LocationBoston, MA
12/02/14
through
12/03/14
26th Annual Piper Jaffray Healthcare Conference
LocationNew York City, NY US
12/03/14
Genetic Rx Conference
LocationBoston, ME
12/03/14
through
12/06/14
Neurodegenerative Diseases: Biology & Therapeutics
LocationCold Spring Harbor, NY
12/06/14
through
12/09/14
56th ASH Annual Meeting and Exposition
LocationSan Francisco, CA
12/08/14 9:00 a.m. ET
Isis Pharmaceuticals’ Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting
Primary IR Contact
D. Wade Walke, Ph.D.
Vice President, Corporate Communications and Investor Relations
Isis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010
Phone: 760-603-2331

For more information requests, please visit our Information Request page.

If you are interested in Isis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Online Investor Kit

Quickly download files right from our Investor Relations Web site.

Learn More

Financial Tearsheet

Download a brief overview of Isis.

Learn More

News Feeds

Get the latest.

Subscribe

Receive Isis alerts in your email.

Sign Up